Published in Medical Letter on the CDC and FDA, November 1st, 2009
The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meets today to review and discuss Acorda's New Drug Application (NDA) for Fampridine-SR for improvement of walking ability in people with multiple sclerosis (MS). About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA